ATE213232T1 - Cyclische und heterocyclische n-substituierte alpha-iminohydroxam- und carbonsäuren - Google Patents

Cyclische und heterocyclische n-substituierte alpha-iminohydroxam- und carbonsäuren

Info

Publication number
ATE213232T1
ATE213232T1 AT96938052T AT96938052T ATE213232T1 AT E213232 T1 ATE213232 T1 AT E213232T1 AT 96938052 T AT96938052 T AT 96938052T AT 96938052 T AT96938052 T AT 96938052T AT E213232 T1 ATE213232 T1 AT E213232T1
Authority
AT
Austria
Prior art keywords
iminohydroxamic
heterocyclic
cyclic
carboxylic acids
substituted alpha
Prior art date
Application number
AT96938052T
Other languages
German (de)
English (en)
Inventor
Werner Thorwart
Wilfried Schwab
Manfred Schudok
Burkhard Haase
Eckart Bartnik
Klaus-Ulrich Weithmann
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26020318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE213232(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE1995142189 external-priority patent/DE19542189A1/de
Priority claimed from DE1996112298 external-priority patent/DE19612298A1/de
Application filed by Hoechst Ag filed Critical Hoechst Ag
Application granted granted Critical
Publication of ATE213232T1 publication Critical patent/ATE213232T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
AT96938052T 1995-11-13 1996-11-04 Cyclische und heterocyclische n-substituierte alpha-iminohydroxam- und carbonsäuren ATE213232T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1995142189 DE19542189A1 (de) 1995-11-13 1995-11-13 Cyclische N-substituierte alpha-Iminohydroxamsäuren
DE1996112298 DE19612298A1 (de) 1996-03-28 1996-03-28 Heterocyclische N-substituierte alpha-Iminohydroxamsäuren
PCT/EP1996/004776 WO1997018194A1 (de) 1995-11-13 1996-11-04 CYCLISCHE UND HETEROCYCLISCHE N-SUBSTITUIERTE α-IMINOHYDROXAM- UND CARBONSÄUREN

Publications (1)

Publication Number Publication Date
ATE213232T1 true ATE213232T1 (de) 2002-02-15

Family

ID=26020318

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96938052T ATE213232T1 (de) 1995-11-13 1996-11-04 Cyclische und heterocyclische n-substituierte alpha-iminohydroxam- und carbonsäuren

Country Status (20)

Country Link
US (3) US6207672B1 (OSRAM)
EP (1) EP0861236B2 (OSRAM)
JP (1) JP4638560B2 (OSRAM)
KR (1) KR100475206B1 (OSRAM)
CN (1) CN1131215C (OSRAM)
AT (1) ATE213232T1 (OSRAM)
AU (1) AU707707B2 (OSRAM)
BR (1) BR9611479B1 (OSRAM)
CA (1) CA2237590C (OSRAM)
CZ (1) CZ297550B6 (OSRAM)
DE (1) DE59608740D1 (OSRAM)
DK (1) DK0861236T4 (OSRAM)
ES (1) ES2170884T5 (OSRAM)
HU (1) HU223086B1 (OSRAM)
MX (1) MX9803753A (OSRAM)
PL (1) PL186869B1 (OSRAM)
PT (1) PT861236E (OSRAM)
RU (1) RU2164914C2 (OSRAM)
TR (1) TR199800849T2 (OSRAM)
WO (1) WO1997018194A1 (OSRAM)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500948B1 (en) 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
EA003294B1 (ru) * 1995-12-08 2003-04-24 Агурон Фармасьютикалс, Инк. Ингибиторы металлопротеиназы, фармацевтические композиции, их содержащие, и их фармацевтические применения
FR2748026B1 (fr) * 1996-04-26 1998-06-05 Adir Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
HUP0000210A3 (en) * 1996-08-28 2001-07-30 Procter And Gamble Co Cincinna Heterocyclic compounds as metalloprotease inhibitors and use of them for producing pharmaceutical compisitions
US5929097A (en) * 1996-10-16 1999-07-27 American Cyanamid Company Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US6228869B1 (en) 1996-10-16 2001-05-08 American Cyanamid Company Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US5962481A (en) * 1996-10-16 1999-10-05 American Cyanamid Company Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US6548524B2 (en) 1996-10-16 2003-04-15 American Cyanamid Company Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US5977408A (en) * 1996-10-16 1999-11-02 American Cyanamid Company Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US5804593A (en) * 1996-10-22 1998-09-08 Pharmacia & Upjohn Company α-Amino sulfonyl hydroxamic acids as matrix metalloproteinase inhibitors
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
SG103322A1 (en) 1996-10-30 2004-04-29 Tanabe Seiyaku Co S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof
US6376506B1 (en) 1997-01-23 2002-04-23 Syntex (U.S.A.) Llc Sulfamide-metalloprotease inhibitors
EP0958287B2 (en) * 1997-01-23 2008-04-09 F. Hoffmann-La Roche Ag Sulfamide-metalloprotease inhibitors
ZA98376B (en) * 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
DE19719817A1 (de) * 1997-05-13 1998-11-19 Hoechst Ag Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren
WO1999006410A1 (en) * 1997-08-04 1999-02-11 Amgen Inc. Hydroxamic acid substituted fused heterocyclic metalloproteinase inhibitors
KR20010030935A (ko) * 1997-10-06 2001-04-16 윌리암 에이취 캘넌, 에곤 이 버그 매트릭스 메탈로프로테이나제 및 종양괴사인자-α 전환효소 억제제로서의 오르토-설폰아미도 바이사이클릭헤테로아릴 하이드록삼산의 제조 및 용도
US6130220A (en) * 1997-10-16 2000-10-10 Syntex (Usa) Inc. Sulfamide-metalloprotease inhibitors
FR2771095B1 (fr) * 1997-11-14 1999-12-17 Adir Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6335329B1 (en) 1997-12-19 2002-01-01 Amgen Inc. Carboxylic acid substituted heterocycles, derivatives thereof and methods of use
US6107291A (en) * 1997-12-19 2000-08-22 Amgen Inc. Azepine or larger medium ring derivatives and methods of use
BR9907746A (pt) * 1998-01-27 2000-10-17 American Cyanamid Co ácidos 2,3,4,5-tetraidro-1h[1,4]-benzodiazepina-3-hidroxâmic os como inibidores de matriz de metaloproteinase
US6071903A (en) * 1998-01-27 2000-06-06 American Cyanamid Company 2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepine-3-hydroxyamic acids
JP2002514647A (ja) 1998-05-14 2002-05-21 デュポン ファーマシューティカルズ カンパニー メタロプロテイナーゼ阻害薬としての新規な置換アリールヒドロキサム酸
WO2000023443A1 (en) * 1998-10-22 2000-04-27 Akzo Nobel N.V. Tetrahydropyridopyridine derivatives and intermediates for producing the same
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
US6358980B1 (en) 1999-01-27 2002-03-19 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
AR022423A1 (es) * 1999-01-27 2002-09-04 American Cyanamid Co Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6544984B1 (en) 1999-01-27 2003-04-08 American Cyanamid Company 2,3,4,5-tetrahydro-1H-(1,4)benzodiazepine-3-hydroxamic acids
GB9903598D0 (en) * 1999-02-18 1999-04-07 Univ Manchester Connective tissue healing
GT200000203A (es) 1999-12-01 2002-05-24 Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas.
GB0011409D0 (en) * 2000-05-11 2000-06-28 Smithkline Beecham Plc Novel compounds
MXPA01013172A (es) 2001-02-14 2002-08-21 Warner Lambert Co Inhibidores sulfonamida de metaloproteinasa de matriz.
FR2821842B1 (fr) * 2001-03-07 2003-05-09 Servier Lab Nouveaux derives d'inhibiteurs de mettalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2003016248A2 (en) 2001-08-17 2003-02-27 Bristol-Myers Squibb Company Patent Department Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace)
CN1610661A (zh) 2001-11-01 2005-04-27 惠氏控股公司 用作基质金属蛋白酶和tace的抑制剂的丙二烯芳基磺酰胺异羟肟酸
RU2223703C2 (ru) * 2002-02-13 2004-02-20 Иркутский государственный институт усовершенствования врачей Способ лечения передней хронической нестабильности коленного сустава
DE10209299A1 (de) * 2002-03-02 2003-09-18 Aventis Pharma Gmbh Cyclische N-substituierte alpha-Iminocarbonsäuren zur selektiven Inhibierung von Kollagenase
US6716853B2 (en) 2002-03-02 2004-04-06 Aventis Pharma Deutschland Gmbh Cyclic N-substituted alpha-imino carboxylic acids for selective inhibition of collogenase
US7199155B2 (en) * 2002-12-23 2007-04-03 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
AU2003292724A1 (en) * 2002-12-27 2004-07-29 Japan Tobacco Inc. Fused n-containing heterocyclic compounds and medicinal use thereof
DE10300015A1 (de) * 2003-01-03 2004-07-15 Aventis Pharma Deutschland Gmbh Iminosäurederivate als Inhibitoren von Matrix-Metallproteinasen
DE10344936A1 (de) 2003-09-27 2005-04-21 Aventis Pharma Gmbh Bicyclische Iminosäurederivate als Inhibitoren von Matrix-Metalloproteinasen
US7205315B2 (en) 2003-09-27 2007-04-17 Sanofi-Aventis Deutschland Gmbh Bicyclic imino acid derivatives as inhibitors of matrix metalloproteinases
DE10351904A1 (de) * 2003-11-06 2005-06-09 Aventis Pharma Deutschland Gmbh Verfahren zur Herstellung von cyclischen N-substituierten alpha-Iminocarbonsäure
US7244845B2 (en) * 2003-11-06 2007-07-17 Sanofi-Aventis Deutschland Gmbh Process for preparing cyclic N-substituted alpha-imino carboxylic acids
DE102004004974A1 (de) * 2004-01-31 2005-08-18 Aventis Pharma Deutschland Gmbh Thieno-Iminosäure-Derivate als Inhibitoren von Matrix-Metalloproteinasen
US7705017B2 (en) * 2004-05-03 2010-04-27 En Vivo Pharmaceuticals, Inc. Compounds for treatment of neurodegenerative diseases
DE102004031620A1 (de) * 2004-06-30 2006-02-02 Sanofi-Aventis Deutschland Gmbh 4-Trifluormethoxyphenoxybenzol-4`-sulfonsäuren, Verfahren zu ihrer Herstellung und Verwendung in Arzneimitteln
DE102004031850A1 (de) * 2004-06-30 2006-01-26 Sanofi-Aventis Deutschland Gmbh Substituirte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
US7601838B2 (en) * 2004-12-28 2009-10-13 Council Of Scientific And Industrial Research 2-Alkyl/aryl sulphonyl-1,2,3,4-tetrahydro-9H-pyrido (3,4-b) indole-3-carboxylic acid esters/amides useful as antithrombotic agents
DE102005002500A1 (de) 2005-01-19 2006-07-27 Sanofi-Aventis Deutschland Gmbh Tetrahydrofuranderivate als Inhibitoren von Matrix-Metalloproteinasen
DE102005015040A1 (de) * 2005-03-31 2006-10-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
CA2606598C (en) 2005-05-13 2014-12-23 Topotarget Uk Limited Pharmaceutical formulations of hdac inhibitors
WO2007045661A1 (en) * 2005-10-20 2007-04-26 Nordic Bioscience Diagnostics A/S Detection or quantification of aggrecan and its fragments
GB0526257D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
DK2041181T3 (da) * 2006-06-08 2011-08-29 Helmholtz Zentrum Muenchen Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi
ES2658964T3 (es) * 2007-08-03 2018-03-13 Nucitec S.A. De C.V. Composiciones y métodos para el tratamiento y la prevención de la osteoartritis
CA2691529C (en) 2007-08-07 2016-01-05 Abbott Gmbh & Co. Kg Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
BRPI0821247A2 (pt) 2007-12-14 2015-06-16 Univ Georgetown Inibidores de histona deacetilase
CN104352492B (zh) * 2008-04-24 2017-12-05 Msd K.K.公司 以芳基磺酰基衍生物作为有效成分的长链脂肪酸延长酶抑制剂
CA2730708A1 (en) * 2008-07-14 2010-01-21 Novartis Ag Selective hydroxamic acid based mmp-12 and mmp-13 inhibitors
FR2947270B1 (fr) 2009-06-30 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
FR2947268B1 (fr) 2009-06-30 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
US20140275108A1 (en) 2013-03-15 2014-09-18 Galderma Research & Development Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics
US20190008828A1 (en) 2015-12-28 2019-01-10 The U.S.A., As Represented By The Secretary Department Of Health And Human Services Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells
ES2695533T3 (es) 2016-02-01 2019-01-08 Galderma Res & Dev Compuestos de bencenosulfonamida, método para su síntesis y uso de los mismos en medicina y cosméticos
CA3082972C (en) 2017-11-27 2022-10-11 Council Of Scientific & Industrial Research Indole (sulfomyl) n-hydroxy benzamide derivatives as selective hdac inhibitors
WO2025224168A1 (en) 2024-04-24 2025-10-30 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
CN119565781B (zh) * 2024-12-20 2026-01-02 中南大学 一种金属离子-含氮芳杂环配合物捕收剂及其制备方法和在钨矿浮选中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES391542A1 (es) * 1970-06-02 1975-09-16 Hokuriku Pharmaceutical Un procedimiento para la preparacion de nuevos derivados de isoquinobenzodiazepina.
TW201303B (OSRAM) * 1990-07-05 1993-03-01 Hoffmann La Roche
JPH04210675A (ja) † 1990-12-13 1992-07-31 Otsuka Pharmaceut Co Ltd ベンゼン誘導体
US5219851A (en) * 1991-03-05 1993-06-15 Warner-Lambert Company Tetrahydroisoquinoline-type renin inhibiting peptides
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
FR2701480B1 (fr) * 1993-02-15 1995-05-24 Sanofi Elf Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant.
JPH10501806A (ja) † 1994-06-22 1998-02-17 ブリティッシュ バイオテック ファーマシューティカルズ リミテッド 金属タンパク質分解酵素阻害剤
DE10003007C2 (de) * 2000-01-25 2002-06-13 Schunk Metall & Kunststoff Erdungskontakt

Also Published As

Publication number Publication date
KR19990067685A (ko) 1999-08-25
DE59608740D1 (de) 2002-03-21
DK0861236T4 (da) 2006-12-18
CA2237590C (en) 2011-07-19
BR9611479B1 (pt) 2009-01-13
KR100475206B1 (ko) 2005-12-16
EP0861236B2 (de) 2006-08-16
ES2170884T5 (es) 2007-04-01
PL186869B1 (pl) 2004-03-31
US20030176432A1 (en) 2003-09-18
MX9803753A (es) 1998-10-31
US20010011134A1 (en) 2001-08-02
PT861236E (pt) 2002-07-31
US6207672B1 (en) 2001-03-27
US6573277B2 (en) 2003-06-03
CA2237590A1 (en) 1997-05-22
ES2170884T3 (es) 2002-08-16
JP2000500145A (ja) 2000-01-11
HUP9903405A3 (en) 2000-12-28
CZ297550B6 (cs) 2007-02-07
CN1202156A (zh) 1998-12-16
EP0861236B1 (de) 2002-02-13
DK0861236T3 (da) 2002-05-21
AU707707B2 (en) 1999-07-15
HUP9903405A1 (hu) 2000-04-28
EP0861236A1 (de) 1998-09-02
US6815440B2 (en) 2004-11-09
AU7562496A (en) 1997-06-05
JP4638560B2 (ja) 2011-02-23
HU223086B1 (hu) 2004-03-29
WO1997018194A1 (de) 1997-05-22
RU2164914C2 (ru) 2001-04-10
PL326702A1 (en) 1998-10-26
TR199800849T2 (xx) 1998-07-21
BR9611479A (pt) 1999-07-13
CZ145398A3 (cs) 1998-08-12
CN1131215C (zh) 2003-12-17

Similar Documents

Publication Publication Date Title
ATE213232T1 (de) Cyclische und heterocyclische n-substituierte alpha-iminohydroxam- und carbonsäuren
ATE427300T1 (de) Heterocyclisch substituierte amide als calpainhemmer
ATE230757T1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
ATE151633T1 (de) Isoxazol-4-carbonsäureamide und hydroxyalkyliden- cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung
EA200100524A1 (ru) Амиды антраниловой кислоты и их применение в качестве лекарственных средств
BR9810841A (pt) Inibidores de metaloprotease alicìclicos
DE69213814D1 (de) Melatoninderivate zur Behandlung von Schlafstörungen und zur Pre-Anästhesie
NO20030724D0 (no) Anvendelse av derivater av valproinsyreamider og 2- valproensyreamider for terapi eller prevensjon av smerte- og/eller hodepinelidelser
DE69232929D1 (de) Saccharinderivate als proteolytische Enzyminhibitoren
ATE218142T1 (de) Nitratester von corticoid verbindungen und die therapeutische verwendungen davon
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
ATE264321T1 (de) Zyklisch imid-substituierte pyridylalkan-, alken-,und alkin- carboxamid-derivate, verwendbar als zytostatische und immunosuppressive mittel
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
DE69613693D1 (de) 2-heteroarylalkenylderivate der cyclopentano-heptan(heptaen)säure als therapeutisches mittel zur behandlung des erhöhten augeninnendruckes
YU48698A (sh) Karboksamidni derivati pirolidina, piperidina i heksahidroazepina za lečenje oboljenja na bazi tromboze
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
DE69834500D1 (de) Xanthinderivative zur behandlung von hirnischämie
DE69500673D1 (de) Arzneimittel zur therapeutischen und prophylaktischen Behandlung von Krankheiten, die durch Hyperplasie der glatten Muskelzellen bedingt sind
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
DE69431199D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Schlafstörungen
ATE136896T1 (de) Piperidylmethyl substituierte chromanderivate als wirkstoffe zur behandlung von erkrankungen des zentralnervensystems
CY1106155T1 (el) Χρηση παραγωγων 3-βενζολοφαινυλοξικων οξεων για την αντιμετωπιση διαταραχων του αμφιβληστροειδους
TR199901385T2 (xx) Piperidin t�revleri.
DE69736180D1 (de) Behandlung von manischen erkrankungen
DE60024969D1 (de) 2-methyl-3-butenyl-1-pyrophosphorsäuresalze und mittel zur behandlung von lymphozyten

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner